Nature Aging examines why the menopause transition remains poorly defined in clinical and research settings, where staging still depends largely on retrospective menstrual history and symptom recall rather than objective markers. Sharper characterization of perimenopause matters for longevity because this window involves accelerated shifts in cardiovascular, skeletal, metabolic and cognitive trajectories that set the trajectory for decades afterward.
Key Points
- Perimenopause staging relies on imprecise retrospective menstrual and symptom data
- Transition window drives cardiovascular, bone, metabolic and cognitive trajectory shifts
- Better biomarkers would enable earlier, individualized intervention timing
Longevity Analysis
The years surrounding the final menstrual period compress several decades of physiological change into a short interval, and the absence of precise staging means intervention is often timed by symptom severity rather than underlying biology. Hormonal withdrawal during this period alters vascular tone, thermoregulatory control, sleep architecture, bone turnover and lipid handling simultaneously — signals frequently attributed to aging or stress rather than to a defined endocrine transition. Resolving that ambiguity converts a blurred clinical category into a measurable window where sleep, resistance training, cardiometabolic monitoring and hormone therapy decisions can be timed deliberately rather than reactively.
Original published by Nature Aging, by Anna Kriebs.